Page last updated: 2024-11-10

ra vii

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

RA VII: structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID3034401
CHEMBL ID289601
MeSH IDM0128088

Synonyms (19)

Synonym
ra vii
bouvardin, 6-(3-hydroxy-n,o-dimethyl-l-tyrosine)-5-(n-methyl-l-tyrosine)-
methylether of tpc-a
6-(3-hydroxy-n,o-dimethyl-l-tyrosine)-5-(n-methyl-l-tyrosine)bouvardin
CHEMBL289601
hvm25o0351 ,
unii-hvm25o0351
86229-97-2
MBQKTLYFUYNAPZ-FEZMQHRXSA-N
ra-700
cyclo(d-alanyl-l-alanyl-n,o-dimethyl-l-tyrosyl-l-alanyl-n-methyl-l-tyrosyl-3-hydroxy-n,o-dimethyl-l-tyrosyl), cyclic (5->6)-ether
ra-vii
ravii
(1s,4r,7s,10s,13s,16s)-24-methoxy-10-[(4-methoxyphenyl)methyl]-4,7,9,13,15,29-hexamethyl-22-oxa-3,6,9,12,15,29-hexazatetracyclo[14.12.2.218,21.123,27]tritriaconta-18,20,23,25,27(31),32-hexaene-2,5,8,11,14,30-hexone
Q27280126
DTXSID701006656
2,5,11-trihydroxy-24-methoxy-10-[(4-methoxyphenyl)methyl]-4,7,9,13,15,29-hexamethyl-22-oxa-3,6,9,12,15,29-hexaazatetracyclo[14.12.2.2~18,21~.1~23,27~]tritriaconta-2,5,11,18,20,23(31),24,26,32-nonaene-8,14,30-trione
FS-7842
AKOS040747341
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (8)

Assay IDTitleYearJournalArticle
AID371567Cytotoxicity against mouse P388 cells2008Bioorganic & medicinal chemistry letters, Dec-15, Volume: 18, Issue:24
Design and synthesis of a bis(cycloisodityrosine) analogue of RA-VII, an antitumor bicyclic hexapeptide.
AID657047Cytotoxicity against mouse P388 cells2012Bioorganic & medicinal chemistry letters, Apr-15, Volume: 22, Issue:8
Synthesis of [Tyr-5-Ψ(CH2NMe)-Tyr-6]RA-VII, a reduced peptide bond analogue of RA-VII, an antitumor bicyclic hexapeptide.
AID317208Cytotoxicity against mouse P388 cells2008Bioorganic & medicinal chemistry letters, Jan-15, Volume: 18, Issue:2
A novel bicyclic hexapeptide, RA-XVIII, from Rubia cordifolia: structure, semi-synthesis, and cytotoxicity.
AID591598Cytotoxicity against mouse P388 cells2011Bioorganic & medicinal chemistry, Apr-01, Volume: 19, Issue:7
Per-N-methylated analogues of an antitumor bicyclic hexapeptide RA-VII.
AID434131Cytotoxicity against mouse P388 cell2009European journal of medicinal chemistry, Sep, Volume: 44, Issue:9
2D- and 3D-QSAR studies on 54 anti-tumor Rubiaceae-type cyclopeptides.
AID1059469Cytotoxicity against human HCT116 cells after 48 hrs by MTT assay2013Bioorganic & medicinal chemistry letters, Dec-15, Volume: 23, Issue:24
Aza-cycloisodityrosine analogue of RA-VII, an antitumor bicyclic hexapeptide.
AID224494In vitro inhibition of protein synthesis in tobacco mosaic virus mRNA-encoded proteins in rabbit reticulocyte lysate2000Journal of medicinal chemistry, Nov-02, Volume: 43, Issue:22
Inhibition of protein synthesis by didemnins: cell potency and SAR.
AID1059470Cytotoxicity against human HL60 cells after 48 hrs by MTT assay2013Bioorganic & medicinal chemistry letters, Dec-15, Volume: 23, Issue:24
Aza-cycloisodityrosine analogue of RA-VII, an antitumor bicyclic hexapeptide.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (33)

TimeframeStudies, This Drug (%)All Drugs %
pre-19905 (15.15)18.7374
1990's9 (27.27)18.2507
2000's12 (36.36)29.6817
2010's5 (15.15)24.3611
2020's2 (6.06)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 18.70

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index18.70 (24.57)
Research Supply Index3.61 (2.92)
Research Growth Index4.68 (4.65)
Search Engine Demand Index15.26 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (18.70)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials2 (5.88%)5.53%
Reviews2 (5.88%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other30 (88.24%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]